Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 8/20 | 0.58 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27776938 | 0.98 | CA2 (0.57) | CA2MAOBPSMB8PSMB5MAOA | |
| SCHEMBL12655257 | 0.86 | MAOB (0.73) | CA2MAOBMAOACYP17A1CYP19A1 | |
| SCHEMBL1252500 | 0.83 | CA2 (0.51) | CA2MAOBPSMB8PSMB5MAOA | |
| SCHEMBL6511944 | 0.83 | MAOB (0.63) | CA2MAOBPSMB8PSMB5MAOA | |
| SCHEMBL3799544 | 0.80 | CA2 (0.49) | CA2MAOBPSMB8PSMB5MAOA | |
| SCHEMBL6511946 | 0.80 | MAOB (0.71) | CA2MAOBPSMB8PSMB5CYP17A1 | |
| SCHEMBL21807603 | 0.80 | MAOB (0.51) | CA2MAOBPSMB8PSMB5TP53 | |
| SCHEMBL2095984 | 0.79 | MAOB (0.55) | CA2MAOBPSMB8PSMB5MAOA | |
| SCHEMBL9634215 | 0.79 | CA2 (0.60) | CA2MAOBPSMB8PSMB5MAOA | |
| SCHEMBL1271520 | 0.79 | CA2 (0.59) | CA2MAOBPSMB8PSMB5MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | claimed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | claimed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023107673-A2 | CLEAVABLE DISULFIDE LINKERS AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| CN-115521325-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| CN-114907389-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20080221193-A1 | 3-AMINO CHROMANE DERIVATIVES | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1828167-A2 | ACRYLAMIDE DERIVATIVES AS ANTIBIOTIC AGENTS | Affinium Pharmaceuticals, Inc. (CA) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007053131-A2 | ACRYLAMIDE DERIVATIVES AS ANTIBIOTIC AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-05-10 | — | — | WO | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
| WO-2005002500-A2 | INHIBITORS OF CORONAVIRUS | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-1992017464-A1 | PHARMACOLOGICALLY ACTIVE α-AMINOETHYL-2-BENZOFURANE METHANOLS SUBSTITUTED IN POSITION 3 | NOE CHRISTIAN R (AT) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CA2 4029/4885MAOB 225/4885PSMB8 3667/4885 |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | CA2 3658/4885MAOB 2399/4885PSMB8 241/4885 |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CA2 716/4885MAOB 517/4885PSMB8 1852/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | CA2 1224/4885MAOB 4172/4885PSMB8 1387/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | CA2 2157/4885MAOB 1178/4885PSMB8 3240/4885 |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | HTR5A, HTR2C, HTR1D | CA2 4877/4885MAOB 315/4885PSMB8 1735/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | CA2 4272/4885MAOB 2865/4885PSMB8 963/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CA2 716/4885MAOB 517/4885PSMB8 1852/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | CA2 2330/4885MAOB 1085/4885PSMB8 1079/4885 |
| US-20080221193-A1 | 3-AMINO CHROMANE DERIVATIVES | HTR3C, HTR3A, HTR2C | CA2 2032/4885MAOB 74/4885PSMB8 3873/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | CA2 3127/4885MAOB 3724/4885PSMB8 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.